Heidelberg Pharma AG (XTER:HPHA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:HPHA Heidelberg Pharma AG XTER:HPHA
51 GF Score
Price €2.49
GF Value €2.55
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XTER:HPHA
51GF Score
Heidelberg Pharma AG XTER:HPHA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.49 is trading 2.4% below its estimated GF Value™ of €2.55. GuruFocus considers Heidelberg Pharma AG to be Fairly Valued.

Key valuation signals for XTER:HPHA:

  • Dividends Received:
  • GF Value™: €2.55 vs. price of €2.49 (2.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a German biopharmaceutical company focused on oncology, specializing in antibody drug conjugates (ADCs) that combine the targeting specificity of antibodies with cytotoxic payloads to selectively attack cancer cells. Its core platform is ATAC (Antibody Targeted Amanitin Conjugates), based on amanitin, a toxin derived from the death cap mushroom, which acts through a distinct mechanism intended to overcome tumor resistance. The company uses this technology both to develop its own proprietary ADC candidates and in research collaborations and licensing arrangements with pharmaceutical partners. Heidelberg Pharma also provides ADC research and manufacturing services. Its operations span drug discovery, preclinical and clinical development, and production, with activities centered in Germany and partnerships extending internationally. Revenue derives from collaboration and licensing agreements, research funding, and service fees rather than from marketed products.
51GF Score

Get the complete analysis for XTER:HPHA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.49
Price
€2.55
GF Value